

# Key figures

60 staff

20 on-going studies

Over 65000 followed-up patients

# Leadership and expertise

## European projects


**ARITMO** - Arrhythmogenic potential of drugs  
*FP7 Work Package partner*

**Eu-ADR** - Early detection of adverse drug events  
*FP7 Work Package leader*

**SOS** - Safety of NSAIDs  
*FP7 Work Package leader*

**SALT** - Study of Acute Liver Transplant  
*Project leader - project at the request of EMEA*


## Training programmes

**Eu2P** - European Training programme in Pharmacovigilance and Pharmacoepidemiology  
Master's of Science, PhD, Continuing Education  
*FP7 project leader -  funding *

**PEP Master & DIU** - National Master's of Science & Continuing Education postgraduate diploma in Pharmacoepidemiology and Pharmacovigilance  
*Training programme leader - Université Bordeaux 2*

## Expert group and society membership

**ISoP** International Society of Pharmacovigilance  
**ISPE** International Society of Pharmacoepidemiology  
**EACPT** European Association of Clinical Pharmacology and Therapeutics  
**ENCePP** European Network of Centres for Pharmacoepidemiology and Pharmacovigilance



Contacts **Nicholas Moore**  
**Bernard Bégaud - Mathieu Molimard**  
**Annie Fourier-Réglat - Patrick Blin**

## Département de Pharmacologie


Université de Bordeaux  
CHU de Bordeaux  
INSERM U657  
INSERM-CHU CIC 0005  
Bâtiment du Tondu - Case 41  
146, rue Léo Saignat  
33076 Bordeaux Cedex  
FRANCE

[www.pharmacoepi.eu](http://www.pharmacoepi.eu)

Tel.: +33 5 57 57 15 60 / 46 75

Fax: +33 5 57 57 47 40

[pharmacoepi@u-bordeaux2.fr](mailto:pharmacoepi@u-bordeaux2.fr)



Département hospitalo-universitaire de  
**Pharmacologie de Bordeaux**

Experimental Pharmacology

Clinical Pharmacology

Pharmacotoxicology

**Pharmacoepidemiology**

Pharmacovigilance

Pharmacodependence



**Inserm**  
Institut national  
de la santé et de la recherche médicale



# Medicines evaluation

We are highly skilled in the full process of real life **medicines evaluation**.

We have in house competencies in Medicine, Pharmacy, Pharmacology, Epidemiology and Biostatistics, and work with a **network** of independent **experts** in Paris, Montreal, Rotterdam, Barcelona, ...

Our staff has continuously expanded and covers the full range of activities involved in **pharmacoepidemiology** studies adhoc and in claims databases.

We cover **major medical fields**: cardiology, hepato-gastroenterology, neurology, oncology, pneumology, rheumatology, spa therapy...

The results of our studies participate in the implementation of guidelines to optimise the benefits and to minimise the risks of medicines to **better public health**.

## Core competencies

### Leadership

Scientific Experts

### Investigation

Coordinator  
Project Managers  
Study Managers  
Clinical Research Assistants  
Administrative Agents

### Support teams

IT & Database  
Statistics  
Data-Management  
Critical Event Validation  
Fund-Raiser  
Lawyer

### Valorisation

Medical Writer Multimedia Support

# Pharmacoepidemiology studies

## EOLE

Impact on mortality of cardiovascular drugs used for secondary prevention of myocardial infarction

*5 492 AMI patients included*

National cohort study at the request of the health authorities, supported by the French Society of Cardiology and the National College of French Cardiologists

## SALT

Study of acute liver failure leading to registration for transplantation in patients exposed to non-steroidal anti-inflammatory drugs

*801 patients expected*

European, multicentre, retrospective case-population study at the request of European Medicines Agency (EMA)  
Transplant centres in 7 EU countries

## EULEV

Prescription modalities and effectiveness of levetiracetam in the treatment of epilepsy in a real-life setting

*794 adults & 156 children included*

National children and adults cohorts study at the request of the health authorities, supported by the French neurologist association

## COLCHIC

Evaluation of chemotherapy practices in patients with colorectal cancer

*204 patients included*

Cohort study evaluating professional practices in a single University Hospital

## ETNA

Evaluation of the survival at 12-months of patients with metastatic colorectal cancer treated by bevacizumab

*413 patients included*

Multiregion multicentre cohort study supported by the national clinical research programme

## SANTORIN

Evaluation of the survival at 24 months of patients with metastatic renal cancer treated by anti-angiogenic drugs

*350 patients expected*

Multiregion multicentre cohort study

## VESUVE

Evaluation of the use and effectiveness of bortezomib, a proteasome inhibitor, in the treatment of multiple myeloma

*784 patients included*

National cohort study at the request of the health authorities

## ABSINTHE

Impact of therapeutic strategy in acute sinusitis in real-life medical practice by GPs and otorhinolaryngologists

*5 693 patients included*

National cohort study at the request of the health authorities

## THEATRE

Impact of the initial strategy for chronic obstructive pulmonary disease exacerbation by GPs and pulmonologists

*5 101 patients included*

National cohort study at the request of the health authorities

## CADEUS

Description of the real-life use of coxibs and traditional non-steroidal anti-inflammatory drugs

*46 554 patients included*

National cohort study at the request of the health authorities  
Use of national reimbursement database and field data

## PRISME

Evaluation of dietetic, physical and psychological care in metabolic syndrome and the quality of life of patients undertaking spa therapy

*139 patients included*

Single centre cohort study

## PSOLEMEE

Evaluation of treatment cost in chronic plaque psoriasis

*770 patients expected*

National medico-economic study

More information on pharmacoepidemiology studies at  
[www.pharmacoepi.eu](http://www.pharmacoepi.eu)

We are part of the INSERM U657 research network